# De-ESCALaTE (NCT01874171)

> Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01874171
- Phase: PHASE3
- Status: UNKNOWN
- Sponsor: University of Warwick
- Conditions: Oropharyngeal Squamous Cell Carcinoma
- Interventions: Cisplatin; Cetuximab
- Enrollment: 334
- Primary outcome: Compare severe (acute and late) toxicity (Grade 3-5) caused by cetuximab and radiotherapy to that caused by cisplatin and radiotherapy.

## Commentary we found

- X threads: 12
- Podcasts: 8
- YouTube: 5

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=de-escalate-nct01874171

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01874171", "email": "<work email>"}; the inbox owner confirms by the emailed link.